GlassScriptPhysician profile
Celyna D Delgado
NPI 1417946625
$789.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $296.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.40 | 2019-2020 | |
| Duchesnay USA Incorporated | $69.12 | 2019 | |
| Astellas Pharma US INC | $67.44 | 2019-2020 | |
| Therapeuticsmd, INC. | $62.44 | 2019-2020 | |
| Daiichi Sankyo INC. | $53.73 | 2019 | |
| Avion Pharmaceuticals | $29.55 | 2019-2020 | |
| Lupin INC. | $23.51 | 2020 | |
| Coopersurgical, INC. | $22.04 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.68 | 2019 | |
| Exeltis, USA INC. | $14.84 | 2020 | |
| Merck Sharp & Dohme LLC | $14.72 | 2019 | |
| Pfizer INC. | $11.56 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celyna Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.